OBI vs. PRTC, OXB, HZD, FARN, VRP, ARIX, CIR, BVXP, 4BB, and AVCT
Should you be buying Ondine Biomedical stock or one of its competitors? The main competitors of Ondine Biomedical include PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.
Ondine Biomedical vs. Its Competitors
Ondine Biomedical (LON:OBI) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.
In the previous week, Ondine Biomedical had 2 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Ondine Biomedical and 0 mentions for PureTech Health. Ondine Biomedical's average media sentiment score of 0.52 beat PureTech Health's score of 0.00 indicating that Ondine Biomedical is being referred to more favorably in the media.
Ondine Biomedical has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
PureTech Health has a consensus price target of GBX 455, indicating a potential upside of 230.67%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Ondine Biomedical.
Ondine Biomedical has a net margin of -873.84% compared to PureTech Health's net margin of -17,620.94%. PureTech Health's return on equity of -21.15% beat Ondine Biomedical's return on equity.
Ondine Biomedical has higher earnings, but lower revenue than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.
20.6% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 79.9% of PureTech Health shares are owned by institutional investors. 36.7% of Ondine Biomedical shares are owned by insiders. Comparatively, 15.9% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Ondine Biomedical and PureTech Health tied by winning 8 of the 16 factors compared between the two stocks.
Get Ondine Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ondine Biomedical Competitors List
Related Companies and Tools
This page (LON:OBI) was last updated on 7/17/2025 by MarketBeat.com Staff
